.jpg "KemPharm (NASDAQ: KMPH)")
Today, the CFO, Secretary & Treasurer of KemPharm (NASDAQ: KMPH), Laduane Clifton, bought shares of KMPH for $3,202.
This recent transaction increases Laduane Clifton’s holding in the company by 33.33% to a total of $13.02K. Following Laduane Clifton’s last KMPH Buy transaction on September 25, 2017, the stock climbed by 2.2%.
See today’s analyst top recommended stocks >>
Currently, KemPharm has an average volume of 85.64K.
Starting in May 2015, KMPH received 83 Buy ratings in a row. Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $12.63, reflecting a -48.5% downside. Seven different firms, including Canaccord Genuity and Cowen & Co., currently also have a Buy rating on the stock.
The insider sentiment on KemPharm has been positive according to 14 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.
